925154-93-4

Basic information

• Product Name: 1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE
• Synonyms: 1-(4-CHLOROBENZYL)-1H-PYRAZOL-3-AMINE;1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE;AKOS PAO-1306;AKOS B001304;ART-CHEM-BB B001304;1-[(4-Chlorophenyl)methyl]pyrazol-3-amine
• CAS NO: 925154-93-4
• Molecular Formula: C₁₀H₁₀ClN₃
• Molecular Weight: 207.66
• Mol File: 925154-93-4.mol

Chemical Properties

• Boiling Point: 398.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• PKA: 3.83±0.10(Predicted)
• CAS DataBase Reference: 1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE(925154-93-4)
• EPA Substance Registry System: 1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE(925154-93-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 925154-93-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE is used as a building block for the synthesis of various pharmaceutical compounds due to its diverse biological activities and potential applications in drug development.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(4-CHLORO-BENZYL)-1H-PYRAZOL-3-YLAMINE is used as a research tool for the development of new drugs, leveraging its pyrazole derivative properties and potential for diverse biological activities.

Upstream product

• 622-95-7 4-chlorobenzyl bromide 
• 1820-80-0 3-aminopyrazole 
• 957478-22-7 1-((4-chlorophenyl)methyl)-3-nitro-1H-pyrazole 

Downstream Products

• 1104806-26-9 5-(1-(4-chlorobenzyl)-1H-pyrazol-3-ylamino)-N-(thiazol-2-yl)pyridine-2-sulfonamide 
• 1104807-13-7 6-(1-(4-chlorobenzyl)-1H-pyrazol-3-ylamino)-N-(thiazol-2-yl)pyridine-3-sulfonamide trifluoroacetate 
• 1104805-92-6 3-chloro-4-(1-(4-chlorobenzyl)-1H-pyrazol-3-ylamino)-N-(thiazol-2-yl)benzenesulfonamide 
• 1104805-94-8 4-(1-(4-chlorobenzyl)-1H-pyrazol-3-ylamino)-2,5-difluoro-N-(thiazol-2-yl)benzenesulfonamide 
• 1104805-67-5 4-(1-(4-chlorobenzyl)-1H-pyrazol-3-ylamino)-3-fluoro-N-(thiazol-2-yl)benzenesulfonamide 
• 588695-59-4 C₁₁H₈ClN₃S 
• 1251930-22-9 C₁₉H₂₂ClN₇OS 

Relevant articles and documents

Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors

The effective treatment for dengue virus infection continues to be a challenge. We herein reported our continued SAR exploration on the spiropyrazolopyridone scaffold. Introducing different substituents at the 3?- or 5?-site of the pyrazolopyridone core or moving the benzyl chain to the adjacent nitrogen led to a significant loss of potency on DENV-2. While a narrow range of substitutions were tolerated at the para-position of the phenyl ring, di-substitution on the phenyl ring is beneficial for DENV-2 potency and has variable influences on DENV-3 potency depending on the exact compound. Among these molecules, compounds 22 (JMX0376) with 4-chloro-3-fluorobenzyl and 24 (JMX0395) with 2,4-bis(trifluoromethyl)benzyl showed the most potent and broadest inhibitory activities against DENV-1 to ?3 with nanomolar to low micromolar EC50 values.

(PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS

A compound of Formula (I) wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

HETEROCYCLIC GAMMA SECRETASE MODULATORS

The invention relates to methods for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome which comprise ad

Pyrazole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.